Analyzing SG&A Spending Trends: Pfizer Inc. vs. Viatris Inc.

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two major players: Pfizer Inc. and Viatris Inc., from 2014 to 2023.

Pfizer Inc.: A Steady Course

Pfizer's SG&A expenses have shown remarkable stability over the years, averaging around $14 billion annually. Despite a dip in 2020, likely due to pandemic-related adjustments, Pfizer's spending rebounded by 2023, reflecting a 27% increase from the 2020 low.

Viatris Inc.: A Growth Trajectory

Viatris, on the other hand, has experienced a significant upward trend. Starting at $1.5 billion in 2014, their SG&A expenses surged by over 200% to reach $4.65 billion in 2023. This growth underscores Viatris's aggressive expansion and market penetration strategies.

These insights highlight the contrasting financial strategies of these pharmaceutical giants, offering a glimpse into their operational priorities.